Welcome to our dedicated page for BIOSTEM TECHNOLOGIES NEW news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on BIOSTEM TECHNOLOGIES NEW stock.
BioStem Technologies is a leading innovator in regenerative therapies, utilizing perinatal tissue to develop and commercialize allografts that change lives. Their proprietary BioREtain® processing method preserves tissue structure and growth factors, setting them apart in the market. With quality brands like AmnioWrap2™ and VENDAJE®, BioStem Technologies is at the forefront of regenerative medicine.
Rhea-AI Summary
BioStem Technologies Inc. CEO, Jason Matuszewski, will present at the LD Micro Invitational Conference to discuss the company's growth in 2023 and future plans for 2024, including the successful launch of Amniowrap2™. The conference will feature presentations from 80 companies with one-on-one meeting opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. (BSEM) reported exceptional financial results for the fourth quarter and full year 2023, with revenue reaching $11.5 million, a 1,355% year-over-year growth. The successful commercial launch of AmnioWrap2 drove this growth, leading to a gross margin of 95% and an Adjusted EBITDA income of $1.67 million in the fourth quarter. The company also highlighted key operational achievements, including acquisitions, clinical trials initiation, and product portfolio expansion. Despite increased operating expenses, BioStem projects strong growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. (BSEM) will release its fourth quarter 2023 financial results on April 1st, 2024. The company, specializing in regenerative medicine, will host a conference call to discuss the financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) reports a significant increase in net revenues for the fourth quarter of 2023, reaching $11.5 million, and for the full year, reaching $16.7 million. The company highlights the successful launch and widespread acceptance of Amniowrap2™, its innovative placental-derived allograft product. BioStem also announces key operational updates, including commercialization agreements and government contract listings. Recent achievements include the appointment of a new Chief Commercial Officer and the establishment of national pricing for AmnioWrap2TM. The company plans to discuss its financial results in a conference call scheduled for March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.91%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. (BSEM) appoints Shawn McCarrey as Chief Commercial Officer, bringing a strong track record of success and deep experience in regenerative medicine markets. Mr. McCarrey has a proven history of transforming care standards in diverse fields such as regenerative medicine, wound care, and podiatry, with significant achievements in boosting company growth rates and expanding sales forces.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) appoints Patrick Daly to its Board of Directors. Daly brings extensive industry experience and relationships in the Biomaterials and MedTech market segments. He has a successful track record in operations, strategy, sales, marketing, fundraising, and partnership-building.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) announces that the Center for Medicare Services (CMS) has established national pricing for its product, AmnioWrap2™, in all Medicare Administrative Contractors (MAC) regions, effective Jan 1, 2024. The company exclusively commercializes AmnioWrap2™ through Venture Medical LLC, an innovative solutions provider in the U.S. wound care market. The CEO emphasized the significance of this achievement, highlighting the benefit it brings to Medicare patients across the United States. The President of Venture Medical LLC expressed eagerness to provide more clinical results and support formal clinical studies, expecting broad product adoption throughout the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.43%
Tags
-
News
Rhea-AI Summary
BioStem Technologies Inc. (OTC:BSEM) appoints Mr. Thomas J. Dugan as Chairman of the Board. Mr. Dugan brings extensive experience in wound care and surgical fields, having transformed businesses and established new market opportunities. BioStem CEO, Jason Matuszewski, looks forward to benefiting from Mr. Dugan's leadership and industry experience to optimize value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
-
Rhea-AI Summary
BioStem Technologies Inc. (OTC: BSEM) reported financial results for the quarter ended September 30, 2023, showcasing a remarkable year of growth and milestones. The company's earnings call will highlight significant achievements, including securing a CMS Q code for VENDAJE AC®, a successful capital raise, and crucial clinical trials for diabetic foot ulcers. The quarter also saw game-changing partnerships with NovaBay Pharmaceuticals and Venture Medical, reflecting BioStem's dedication to transforming regenerative medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
Rhea-AI Summary
BioStem Technologies Inc. (OTC:BSEM) announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279 for VENDAJE AC® for advanced wound care, effective January 1st, 2024. This code will ensure broader access and reimbursement pathways for the product, marking a significant milestone for the company's portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.8%
Tags
FAQ
What is the current stock price of BIOSTEM TECHNOLOGIES NEW (BSEM)?
The current stock price of BIOSTEM TECHNOLOGIES NEW (BSEM) is $13.1 as of October 15, 2024.
What is the market cap of BIOSTEM TECHNOLOGIES NEW (BSEM)?
The market cap of BIOSTEM TECHNOLOGIES NEW (BSEM) is approximately 234.2M.
What sets BioStem Technologies apart from competitors?
BioStem Technologies differentiates itself with the proprietary BioREtain® processing method that preserves tissue structure and growth factors, ensuring effective regenerative therapies.
What products does BioStem Technologies offer?
BioStem Technologies' portfolio includes quality brands like AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, all aimed at providing cutting-edge regenerative solutions.
Where are BioStem Technologies' products processed?
All BioStem Technologies placental allografts are processed at the FDA-registered and AATB-accredited site in Pompano Beach, Florida, ensuring quality and safety.
How does BioStem Technologies contribute to the wound care market?
BioStem Technologies plays a significant role in the wound care market by leveraging natural properties of perinatal tissue to develop allografts that support wound healing and tissue regeneration.
What is the significance of BioStem Technologies' recent patent approval?
BioStem Technologies' patent approval for their method of processing human amniotic tissue strengthens their intellectual property and positions them as a leader in regenerative medicine.
BIOSTEM TECHNOLOGIES NEW